PMID- 24030742
OWN - NLM
STAT- MEDLINE
DCOM- 20141021
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 27
IP  - 3
DP  - 2014 Mar
TI  - B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a 
      clinically aggressive subset of disease.
PG  - 382-9
LID - 10.1038/modpathol.2013.149 [doi]
AB  - B acute lymphoblastic leukemia (B-ALL) with t(14;19)(q32;p13.1), in which IGH and 
      EPOR are juxtaposed, has been reported rarely. We describe the 
      clinicopathological features of six patients, three men and three women, with a 
      median age of 39 years. Initial and follow-up bone marrow samples were examined 
      from each patient. The clinical, morphologic, and immunophenotypic results were 
      compared with data obtained from conventional cytogenetic analysis and by using 
      home-brew fluorescence in situ hybridization (FISH) probes for IGH at 14q32 and 
      EPOR at 19p13.1. The bone marrow specimens were hypercellular (median 90%; range 
      80-100%), with a median blast count of 90% (range 60-93%). Immunophenotypic 
      analysis performed by flow cytometry demonstrated a stable, precursor B-cell 
      immunophenotype. The t(14;19)(q32;p13.1) was present in all cases with 
      morphologic evidence of disease. The translocation was stable and appeared 
      morphologically subtle on conventional karyotypic analysis. Detection was 
      facilitated using FISH, which confirmed IGH/EPOR rearrangement in all cases. All 
      patients received aggressive multiagent chemotherapy as part of a variety of 
      regimens. Four of six patients achieved an initial complete remission, but all 
      relapsed. At last follow-up, five of six patients had died of disease (median 
      survival, 12 months after diagnosis). We conclude that B-ALL associated with 
      t(14;19)(q32;p13.1) is a distinctive form of disease that is associated with 
      younger patient age and an aggressive clinical course.
FAU - Jaso, Jesse M
AU  - Jaso JM
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Yin, C Cameron
AU  - Yin CC
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Lu, Victoria W
AU  - Lu VW
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Zhao, Ming
AU  - Zhao M
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Abruzzo, Lynne V
AU  - Abruzzo LV
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - You, M James
AU  - You MJ
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Yang, Yaling
AU  - Yang Y
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Luthra, Raja
AU  - Luthra R
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Medeiros, L Jeffrey
AU  - Medeiros LJ
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Lu, Gary
AU  - Lu G
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130913
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (Immunoglobulin Heavy Chains)
RN  - 0 (Receptors, Erythropoietin)
SB  - IM
MH  - Abnormal Karyotype
MH  - Adult
MH  - Aged
MH  - Chromosomes, Human, Pair 14/*genetics
MH  - Chromosomes, Human, Pair 19/*genetics
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunoglobulin Heavy Chains/*genetics
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*genetics/mortality/pathology
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptors, Erythropoietin/*genetics
MH  - Translocation, Genetic
MH  - Young Adult
EDAT- 2013/09/14 06:00
MHDA- 2014/10/22 06:00
CRDT- 2013/09/14 06:00
PHST- 2013/05/26 00:00 [received]
PHST- 2013/06/29 00:00 [revised]
PHST- 2013/07/01 00:00 [accepted]
PHST- 2013/09/14 06:00 [entrez]
PHST- 2013/09/14 06:00 [pubmed]
PHST- 2014/10/22 06:00 [medline]
AID - S0893-3952(22)01828-2 [pii]
AID - 10.1038/modpathol.2013.149 [doi]
PST - ppublish
SO  - Mod Pathol. 2014 Mar;27(3):382-9. doi: 10.1038/modpathol.2013.149. Epub 2013 Sep 
      13.